Unknown

Dataset Information

0

A bioengineered living cell construct activates an acute wound healing response in venous leg ulcers.


ABSTRACT: Chronic nonhealing venous leg ulcers (VLUs) are widespread and debilitating, with high morbidity and associated costs; about $15 billion is spent annually on the care of VLUs in the United States. Despite this, there is a paucity of treatments for VLUs because of the lack of pathophysiologic insight into ulcer development as well as the lack of knowledge regarding biologic actions of existing VLU-targeted therapies. The bioengineered bilayered living cellular construct (BLCC) skin substitute is a U.S. Food and Drug Administration-approved biologic treatment for healing VLUs. To elucidate the mechanisms through which the BLCC promotes healing of chronic VLUs, we conducted a clinical trial (NCT01327937) in which patients with nonhealing VLUs were treated with either standard of care (compression therapy) or the BLCC together with standard of care. Tissue was collected from the VLU edge before and 1 week after treatment, and the samples underwent comprehensive microarray mRNA and protein analyses. Ulcers treated with the BLCC skin substitute displayed three distinct transcriptomic patterns, suggesting that BLCC induced a shift from a nonhealing to a healing tissue response, involving modulation of inflammatory and growth factor signaling, keratinocyte activation, and attenuation of Wnt/?-catenin signaling. In these ways, BLCC application orchestrated a shift from the chronic nonhealing ulcer microenvironment to a distinctive healing milieu resembling that of an acute, healing wound. Our findings provide in vivo evidence in VLU patients of pathways that can be targeted in the design of new therapies to promote healing of chronic VLUs.

SUBMITTER: Stone RC 

PROVIDER: S-EPMC5472448 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

A bioengineered living cell construct activates an acute wound healing response in venous leg ulcers.

Stone Rivka C RC   Stojadinovic Olivera O   Rosa Ashley M AM   Ramirez Horacio A HA   Badiavas Evangelos E   Blumenberg Miroslav M   Tomic-Canic Marjana M  

Science translational medicine 20170101 371


Chronic nonhealing venous leg ulcers (VLUs) are widespread and debilitating, with high morbidity and associated costs; about $15 billion is spent annually on the care of VLUs in the United States. Despite this, there is a paucity of treatments for VLUs because of the lack of pathophysiologic insight into ulcer development as well as the lack of knowledge regarding biologic actions of existing VLU-targeted therapies. The bioengineered bilayered living cellular construct (BLCC) skin substitute is  ...[more]

Similar Datasets

2016-09-01 | GSE84571 | GEO
| S-EPMC7461720 | biostudies-literature
| S-EPMC5147907 | biostudies-literature
| S-EPMC6940587 | biostudies-literature
| S-EPMC9354941 | biostudies-literature
| S-EPMC8505655 | biostudies-literature
| S-EPMC10410353 | biostudies-literature
| S-EPMC10768026 | biostudies-literature
| S-EPMC4269806 | biostudies-literature
| S-EPMC10098114 | biostudies-literature